Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
GALT

GALT - Galectin Therapeutics Inc Stock Price, Fair Value and News

$3.08-0.07 (-2.22%)
Market Closed

Price Targets

GALT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GALT Price Action

Last 7 days

-2.8%

Last 30 days

-24.5%

Last 90 days

-39.2%

Trailing 12 Months

150.4%

GALT RSI Chart

GALT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GALT Valuation

Market Cap

198.6M

Price/Earnings (Trailing)

-5.32

Price/Free Cashflow

-6.49

GALT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

GALT Fundamentals

GALT Earnings

Earnings (TTM)

-37.3M

Earnings Growth (Yr)

27.06%

Earnings Growth (Qtr)

-8.82%

GALT Profitability

Return on Equity

29.77%

Return on Assets

-289.96%

Free Cashflow Yield

-15.41%

GALT Investor Care

Shares Dilution (1Y)

2.73%

Diluted EPS (TTM)

-0.59

GALT Alerts

  • 1 major insider buys and 2 major insider sales recently.

About Galectin Therapeutics Inc

GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
 CEO
 WEBSITEhttps://galectintherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12

Galectin Therapeutics Inc Frequently Asked Questions

GALT is the stock ticker symbol of Galectin Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Galectin Therapeutics Inc is 198.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check GALT's fair value in chart for subscribers.

The fair value guage provides a quick view whether GALT is over valued or under valued. Whether Galectin Therapeutics Inc is cheap or expensive depends on the assumptions which impact Galectin Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GALT.

In the past 10 years, Galectin Therapeutics Inc has provided 0.081 (multiply by 100 for percentage) rate of return.